Erlizumab

Drug Profile

Erlizumab

Alternative Names: Anti-CD18 monoclonal antibody - Genentech; rhuMAb CD18

Latest Information Update: 22 Mar 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Genentech; PDL BioPharma; Roche
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Shock

Most Recent Events

  • 22 Mar 2001 Anti-CD18 monoclonal antibody is now called erlizumab
  • 24 Jan 2001 Discontinued-II for Myocardial infarction in USA (IV)
  • 24 Jan 2001 A study was added to the adverse events and Ischaemic Heart Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top